[Translation] A multicenter, randomized, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety of meflunisal hydrochloride tablets in the treatment of type 2 diabetic nephropathy

主要研究目的：初步评价盐酸美氟尼酮片在2型糖尿病肾病患者中的有效性和安全性。次要研究目的：评价盐酸美氟尼酮片在2型糖尿病肾病患者中的药代动力学特征。

[Translation]

Main study objectives: To preliminarily evaluate the efficacy and safety of meflunisal hydrochloride tablets in patients with type 2 diabetic nephropathy. Secondary study objectives: To evaluate the pharmacokinetic characteristics of meflunisal hydrochloride tablets in patients with type 2 diabetic nephropathy.

Start Date29 Jun 2023

Sponsor / Collaborator

Guangzhou Nanxin Pharma Co Ltd

[+1]

CTR20211769 / CompletedPhase 1

盐酸美氟尼酮片在中国健康受试者中多次给药的安全性、耐受性、药代动力学单中心、随机、双盲、安慰剂平行对照的Ⅰb期临床研究

[Translation] A single-center, randomized, double-blind, placebo-controlled phase Ib clinical study on the safety, tolerability, and pharmacokinetics of meflunisal hydrochloride tablets after repeated administration in healthy Chinese subjects

主要目的：评估中国健康受试者多次口服不同剂量盐酸美氟尼酮片的安全性和耐受性。次要目的：评估中国健康受试者多次口服不同剂量盐酸美氟尼酮片的药代动力学（PK）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of meflunisal hydrochloride tablets in Chinese healthy subjects after repeated oral administration of different doses. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of meflunisal hydrochloride tablets in Chinese healthy subjects after repeated oral administration of different doses.

Start Date28 Oct 2021

Sponsor / Collaborator

Guangzhou Nanxin Pharma Co Ltd

[+1]

CTR20200492 / CompletedPhase 1

盐酸美氟尼酮片在中国健康受试者中的单次给药、剂量递增的安全性、耐受性、药代动力学及食物影响的单中心、随机、双盲、安慰剂平行对照的Ⅰ期临床研究

[Translation] A single-center, randomized, double-blind, placebo-controlled phase I clinical study on the safety, tolerability, pharmacokinetics and food effects of single-dose, dose-escalation of meflunisal hydrochloride tablets in healthy Chinese subjects

主要目的：评估中国健康受试者单次口服不同剂量盐酸美氟尼酮片的安全性和耐受性。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single oral administration of different doses of meflunisal hydrochloride tablets in healthy Chinese subjects.

Start Date01 Sep 2020

Sponsor / Collaborator

Guangzhou Nanxin Pharma Co Ltd

[+1]

100 Clinical Results associated with Mefunidone Hydrochloride

100 Translational Medicine associated with Mefunidone Hydrochloride

100 Patents (Medical) associated with Mefunidone Hydrochloride

Literatures (Medical) associated with Mefunidone Hydrochloride

01 Sep 2024·Biomedicine & Pharmacotherapy

Mefunidone alleviates silica-induced inflammation and fibrosis by inhibiting the TLR4-NF-κB/MAPK pathway and attenuating pyroptosis in murine macrophages

Article

Author: Peng, Zhangzhe ; Meng, Jie ; Jiang, Mao ; Jiang, Guoliang ; Yao, Tingting ; Tao, Lijian ; Zhang, Xiangyu ; Cheng, Xiaoyun ; Dai, Xiaoqing ; Hu, Gaoyun ; Long, Lingzhi ; He, Yijun

AIMSSilicosis is the most common and severe type of pneumoconiosis, imposing a substantial disease burden and economic loss on patients and society. The pathogenesis and key targets of silicosis are not yet clear, and there are currently no effective treatments available. Therefore, we conducted research on mefunidone (MFD), a novel antifibrotic drug, to explore its efficacy and mechanism of action in murine silicosis.METHODSAcute 7-day and chronic 28-day silicosis models were constructed in C57BL/6J mice by the intratracheal instillation of silica and subsequently treated with MFD to assess its therapeutic potential. The effects of MFD on silica-induced inflammation, pyroptosis, and fibrosis were further investigated using immortalized mouse bone marrow-derived macrophages (iBMDMs).RESULTSIn the 7-day silica-exposed mouse models, MFD treatment significantly alleviated pulmonary inflammation and notably reduced macrophage infiltration into the lung tissue. RNA-sequencing analysis of silica-induced iBMDMs followed by gene set enrichment analysis revealed that MFD profoundly influenced cytokine-cytokine receptor interactions, chemokine signaling, and the toll-like receptor signaling pathways. MFD treatment also markedly reduced the secretion of inflammatory cytokines and chemokines from silica-exposed iBMDMs. Moreover, MFD effectively downregulated the activation of the TLR4-NF-κB/MAPK signaling pathway induced by silica and mitigated the upregulation of pyroptosis markers. Additionally, MFD treatment significantly suppressed the activation of fibroblasts and alveolar epithelial cells co-cultured with silica-exposed mouse macrophages. Ultimately, in the 28-day silica-exposed mouse models, MFD administration led to a substantial reduction in the severity of pulmonary fibrosis.CONCLUSIONMFD mitigates silica-induced pulmonary inflammation and fibrosis in mice by suppressing the TLR4-NF-κB/MAPK signaling pathway and reducing pyroptotic responses in macrophages. MFD could potentially emerge as a novel therapeutic agent for the treatment of silicosis.

01 Jul 2024·Biochemical Pharmacology

Mefunidone ameliorates acute liver failure in mice by inhibiting MKK4-JNK pathway

Article

Author: Yang, Huixiang ; He, Xin ; Tang, Jie ; Zhang, Yanqiu ; Gu, Lei ; Ma, Ruixue ; Peng, Zhangzhe ; Li, Shenglan

Acute liver failure (ALF) is a critical condition that can lead to substantial liver dysfunction. It is characterized by complex clinical manifestations and rapid progression, presenting significant challenges in diagnosis and treatment. We investigated the protective effect of mefunidone (MFD), a novel antifibrosis pyridone agent, on ALF in mice, and explored its potential mechanism of action. MFD pretreatment can alleviate lipopolysaccharide (LPS) and d-galactosamine (D-GalN)-induced ALF, reduce hepatocyte apoptosis, and reduce inflammation and oxidative stress. Additionally, MFD alleviated LPS/D-GalN-stimulated reactive oxygen species (ROS) production and cell death in AML12 cells. RNA sequencing enrichment analysis showed that MFD significantly affected the Mitogen-Activated Protein Kinase (MAPK) pathway. In vivo and in vitro experiments showed that MFD inhibited MKK4 and JNK phosphorylation. JNK activation caused by MKK4 and JNK activators could eliminate the therapeutic effect of MFD on AML12. In addition, MFD pretreatment alleviated ConA-induced ALF, reduced inflammation and oxidative stress in mice, and reduced mouse mortality. These results suggest that MFD can potentially protect against ALF, partially by inhibiting the MKK4-JNK pathway, and is a promising new therapeutic drug for ALF.

01 Dec 2022·International Immunopharmacology

Mefunidone ameliorates lipopolysaccharide-induced acute lung injury through inhibiting MAPK signaling pathway and enhancing Nrf2 pathway

Article

Author: Yao, Ting-Ting ; Lv, Xin ; He, Yi-Jun ; Cheng, Xiao-Yun ; Tao, Li-Jian ; Zhang, Yan ; Li, Meng-Yu ; Meng, Jie ; Jiang, Guo-Liang ; He, Rong-Ling ; Li, Qian-Bin ; Hu, Gao-Yun ; Long, Ling-Zhi ; Han, Yuan-Yuan

BACKGROUND AND OBJECTIVEAcute lung injury (ALI) is a life-threatening disease which has high mortality and lacks effective pharmacological treatments. Excessive inflammation and oxidative stress are the key pathogenesis of ALI. Mefunidone (MFD), a novel small molecule compound, displayed anti-inflammation and anti-oxidative stress effects on streptozocin (STZ) and db/db mice in our previous studies. In this study, we aimed to investigate the effects of MFD on lipopolysaccharide (LPS)-induced ALI and explore the potential molecular mechanisms.METHODSWe investigated the effects of MFD on LPS-induced ALI mouse model and LPS-stimulated immortalized mouse bone marrow-derived macrophages (iBMDMs).RESULTSMFD could alleviate pulmonary structure disorder and attenuate pulmonary neutrophils infiltration induced by LPS. MFD could also decreased proinflammatory cytokines release and reduce reactive oxygen species (ROS) generation stimulated by LPS. Further, MFD could significantly reduce LPS-induced phosphorylation levels of mitogen-activated protein kinase (MAPK), increase expression of nuclear factor-erythroid 2 related factor 2 (Nrf2) and restore the expressions of antioxidant enzymes.CONCLUSIONOur results firstly supported that MFD effectively protected LPS-induced ALI against inflammation and oxidative stress through inhibiting MAPK signaling pathway and activating Nrf2 pathway.

100 Deals associated with Mefunidone Hydrochloride

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Type 2 diabetes mellitus with established diabetic nephropathy	Phase 2	CN	Guangzhou Nanxin Pharma Co Ltd	29 Jun 2023
Type 2 diabetes mellitus with established diabetic nephropathy	Phase 2	CN	Central South University	29 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Mefunidone Hydrochloride

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation